Vir Biotechnology names Aziz Sawaf as CFO, effective Oct. 2026

Vir Biotechnology, Inc. (Nasdaq: VIR) has appointed Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective October 5, 2026, according to a company statement.

Sawaf will oversee the company's finance, IT, and investor relations functions. He joins from Theravance Biopharma, Inc., where he served as CFO since 2023 and as Senior Vice President of Operations Strategy since 2025. Before that, he held financial leadership roles of increasing responsibility at Theravance after joining in 2014, and prior to that worked on R&D and commercial finance teams at Gilead Sciences.

Sawaf holds a B.S. in Business Administration from the University of Arizona, an MBA from the University of Southern California's Marshall School of Business, and an MBEE from Johns Hopkins University. He is also a CFA charterholder.

"His experience in driving financial performance across the biotech lifecycle, from clinical development through regulatory approval and commercialization, will be a valuable asset for Vir Biotechnology's next phase of growth," said Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology.

Vir Biotechnology is a clinical-stage biopharmaceutical company with programs focused on chronic hepatitis delta and solid tumor indications.

You May Also Be Interested In

• Raymond James Reiterates Strong Buy Rating on Vir Biotechnology (VIR)
• First Merchants CEO to retire; president set to take over in 2027
• Hershey names Amanda Almond as president of international unit